Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349.HK) Earnings Analysis
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349.HK) next reports earnings on 2026-08-15. Trailing P/E -50.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1349.HK next report earnings?
| Next earnings date | 2026-08-15 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
1349.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 0.00842 HKD | n/a | n/a | n/a |
| 2026-02-27 | -0.14462 HKD | n/a | n/a | n/a |
| 2025-08-15 | 0.00322 HKD | n/a | n/a | n/a |
| 2024-10-25 | 0.01514 HKD | n/a | n/a | n/a |
| 2024-08-12 | 0.07058 HKD | n/a | n/a | n/a |
1349.HK valuation and analyst view
| Trailing P/E | -50.55 |
|---|---|
| Trailing EPS | -0.14702 HKD |
| Price / book | 3.58 |
| Dividend yield | 0.68% |
| Market cap | 0.82B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349.HK)'s next earnings date?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical is next scheduled to report on 2026-08-15.
Did 1349.HK beat earnings last quarter?
Consensus estimate data was not available for 1349.HK's 2026-04-30 report.
What is 1349.HK's current P/E ratio and EPS?
1349.HK trades at a trailing P/E of -50.55 on trailing EPS of -0.1470162692976205 HKD.
What do analysts rate 1349.HK?
1349.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.